Aigen Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Aigen Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,153	Closed	-$1.68M	–	1090
2024 Q4	$1.68M	Buy	20,153 +5,263	+35%	+$432K	0.3%	86
2024 Q3	$1.09M	Buy	14,890 +7,105	+91%	+$534K	0.21%	133
2024 Q2	$533K	Buy	+7,785	New	+$540K	0.1%	288
2023 Q3	–	Sell	-14,220	Closed	-$900K	–	1126
2023 Q2	$900K	Buy	14,220 +5,810	+69%	+$362K	0.13%	226
2023 Q1	$455K	Buy	+8,410	New	+$407K	0.06%	331
2020 Q4	–	Sell	-64,625	Closed	-$1.66M	–	1142
2020 Q3	$1.66M	Buy	+64,625	New	+$1.47M	0.21%	143
2020 Q1	–	Sell	-1,199	Closed	-$41K	–	1622
2019 Q4	$41K	Buy	+1,199	New	+$14.4K	0.01%	839

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Aigen Investment Management's ITCI Position: Q1 2025 in Review

Aigen Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 20,153 shares — an estimated $1.68M sold.

Aigen Investment Management first reported a position in ITCI in Q4 2019 and held it in 7 quarters. The position peaked at $1.68M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Aigen Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Aigen Investment Management sold 20,153 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $1.68M.
Aigen Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 7 quarters.
Aigen Investment Management's Intra-Cellular Therapies Inc. position peaked at $1.68M in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Aigen Investment Management's 13F filing for Q1 2025, filed 12 May 2025.